secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001062822-23-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon reports Q1 net loss of $31.9M; PDUFA for sotagliflozin on track for May 27
--------------------------------------------------------------------------------

- Q1 2023 net loss $31.9M ($0.17/share), compared to $23.5M ($0.16/share) in Q1 2022.
- Cash and investments $105.9M at Mar 31, down from $138.4M at Dec 31, 2022.
- NDA for heart failure drug sotagliflozin has May 27 PDUFA action date; company prepared for prompt US launch.
- R&D spending fell to $12.1M; SG&A rose to $19.1M on commercial launch preparations.
- LX9211 for neuropathic pain advancing; FDA feedback on late-stage development expected in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000018/0001062822-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000018/lxrx-20230502.htm
  HTML page:      https://secwatch.observer/filing/0001062822-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer